*僅供醫(yī)學(xué)專業(yè)人士閱讀參考

重癥肌無(wú)力領(lǐng)域又取得了哪些進(jìn)展？

*以下內(nèi)容僅供在中國(guó)大陸執(zhí)業(yè)的

醫(yī)療衛(wèi)生專業(yè)人士瀏覽。

參考文獻(xiàn)：

[1]Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015 Oct;14(10):1023-36.

[2]Xin H, Harris LA, Aban IB, Cutter G. Examining the Impact of Refractory Myasthenia Gravis on Healthcare Resource Utilization in the United States: Analysis of a Myasthenia Gravis Foundation of America Patient Registry Sample. J Clin Neurol. 2019 Jul;15(3):376-385.

[3]Utsugisawa K Nagane Y Uzawa A Murai H Imai T Suzuki S. Health-related quality of life and treatment strategies in myasthenia gravis. Clin Exp Neuroimmunol. 2020; 11: 209-217

[4]Bril V, Benatar M, Andersen H; MG0002 Investigators. Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial. Neurology. 2021 Feb 9;96(6):e853-e865.

[5]Bril V, Dru?d? A, Grosskreutz J; MG0003 study team. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023 May;22(5):383-394.

[6]Habib AA, et al. Efficacy and Safety of Rozanolixizumab Treatment Cycles in Patients With Generalised Myasthenia Gravis: Final Pooled Analysis of Phase 3 Studies. MGFA 2025. Poster 71.

[7]Vu T, et al. Responder and Minimal Symptom Expression Rates With Rozanolixizumab in Generalised Myasthenia Gravis: Final Pooled Analysis of Phase 3 Studies. MGFA 2025. Poster 206.

[8]Zabeen K, et al. Effect of rozanolixizumab on ocular symptoms in patients with generalized myasthenia gravis: A post hoc item-level analysis of myasthenia gravis-speciffc outcomes in MycarinG. AAN 2025. Poster P1-11-006.

[9]Wallace T, et al. Effect of rozanolixizumab on bulbar and respiratory symptoms in patients with generalized myasthenia gravis: A post hoc item-level analysis of MycarinG. AAN 2025.

[10]Carlo Antozzi, et al. Patient preferences and experience with self-administration of rozanolixizumab in generalised myasthenia gravis: The MG0020 study. MGFA International 2025. Poster 4.

[11]Vera Bril, et al. Self-administration of rozanolixizumab in patients with generalized myasthenia gravis: The MG0020 study. AAN 2025. Poster P1-11-018.

醫(yī)學(xué)界神經(jīng)領(lǐng)域交流群正式開放！

加入我們吧！

[CN-RZ-2500050 有效期截止：2027年5月] 本內(nèi)容僅供醫(yī)療衛(wèi)生專業(yè)人士閱讀，所含信息不應(yīng)代替醫(yī)療衛(wèi)生專業(yè)人士提供的醫(yī)療建議，也不建議醫(yī)療衛(wèi)生專業(yè)人士超出說(shuō)明書范圍使用所涉及的藥物。

*此文僅用于向醫(yī)學(xué)人士提供科學(xué)信息，不代表本平臺(tái)觀點(diǎn)

*"醫(yī)學(xué)界"力求所發(fā)表內(nèi)容專業(yè)、可靠，但不對(duì)內(nèi)容的準(zhǔn)確性做出承諾；請(qǐng)相關(guān)各方在采用或以此作為決策依據(jù)時(shí)另行核查。